Biopharmaceutical company Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) said on Friday that NHS England has implemented the use of Evkeeza (evinacumab) for eligible adults and adolescents with homozygous familial hypercholesterolemia (HoFH).

This decision follows positive guidance from the National Institute for Health and Care Excellence (NICE).

Evkeeza, a monoclonal antibody that inhibits the ANGPTL3 protein, is designed to lower levels of LDL-C, or bad cholesterol. The drug will be available at seven hospital trusts in England, providing a significant treatment option for patients with this rare and serious condition.

HoFH is a genetic disorder characterised by extremely high levels of LDL-C, which can lead to premature heart disease.